Page History

Jeffrey Brown, TriNetX

Jeffrey Brown, PhD, Chief Scientific Officer at TriNetX and part-time lecturer part-time at Harvard Medical School (HMS), is an internationally recognised expert in using real-world data to support the evidentiary needs of regulatory agencies and medical product sponsors. He is also an expert in assessing data quality of real-world data resources. Dr Brown focuses on the value of collaborative research with an emphasis on federated networks. He has expertise in assessing the fitness-for-use of real-world data and matching questions to methods to data to generate robust evidence. He has nearly 20 years of experience facilitating large-scale, multi-institutional observational research through using distributed health data networks to support a learning health system and using electronic health data to support decision-making.

In his previous role as Associate Professor at Harvard Medical School, Dr Brown served as the Lead Data Scientist for the FDA Sentinel Operations Center and as a member of the Sentinel Operations Center Executive Committee. He has also been Principal Investigator of the analytic coordinating centre for the Innovation in Medical Evidence Development and Surveillance (IMEDS) programme and the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC). While at Harvard he also served as PI of several industry-sponsored multi-site pharmacoepidemiologic studies to support FDA and EMA regulatory requirements. Dr Brown holds a master’s degree in economics from Tufts University and a PhD in Social Policy from Brandeis University.

Michèle Arnoe, IQVIA

During her career Michèle Arnoe has followed all the stages of the drug development life cycle, from pre-clinical preclinical research to clinical development and commercializationcommercialisation. She initially worked for the French company Cegedim (technology and services in digital healthcare ecosystemecosystems) to launch their international expansion. In 1999, Michele Michèle joined the global clinical organization Parexel, where she became Vice President for Business Management and Strategy for the European Peri Approval division . She and was responsible for both the sales and project management teams. The organization organisation she built ensured a strong alignment between sales, project design, project management and client objectives.

 Michèle has She also worked for Cerep S.A., leader in pre-clinical preclinical pharmacology, and ADME-Tox services, where she was Global Head of Business Development for 6 six years. Michèle She then joined ScreenCell (a company designing medical devices in support of oncology diagnostics) in  in 2011 as VP Marketing & Business Development.She came  She went back to Cegedim in 2013 as General Manager for France Cegedim Strategic Data and VP Medical Research, then joined again the CRM (Customer Relationship Management) BU managing to manage the Global global account managers team focusing on Large Pharmalarge pharma.

 Following Cegedim’s acquisition by IMSHealth IMS Health, then the IMS-Quintiles IMS merger, Michèle was became Head of Innovation in France. She was then was appointed Head of Global Real World Data Assets, with responsibilities focusing on RWD data visibility across geographies and functions, including access, transformation , and compliant usage thus aiming at , with the aim of leveraging secondary data when appropriate throughout the drug lifecyclelife cycle.